Advertisement

Search Results

Advertisement



Article Topics

Your search for Mark R. Gilbert, MD matches 9 pages

Showing 1 - 9


2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the individuals at risk for, or with...

ASCO Honors Leaders in Cancer Care With 2018 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

cns cancers

Studies Explore Role of Bevacizumab in Combination Therapies for Glioblastoma

At the 2013 ASCO Annual Meeting, studies evaluating the addition of bevacizumab (Avastin) to standard therapy in newly diagnosed glioblastoma multiforme patients did not meet their primary endpoints. When paired with irinotecan, however, bevacizumab showed activity in MGMT-unmethylated tumors....

cns cancers

Improved Understanding of Glioma Tumor Biology

The management of patients with lower-grade gliomas is evolving. As evidenced by two recent publications in The New England Journal of Medicine,1,2 reviewed in this issue of The ASCO Post, there has been a substantial increase in our knowledge of the molecular characteristics of these neoplasms....

cns cancers

New Molecular Classifications of Gliomas Established

Two studies reported in The New England Journal of Medicine identified new molecular classifications of glioma that capture biologic and prognostic differences. The Cancer Genome Atlas Research Network identified three prognostically significant subtypes of lower-grade glioma that were identified...

cns cancers

Adding Bevacizumab to Radiotherapy and Temozolomide Does Not Improve Overall Survival in Newly Diagnosed Glioblastoma

In a double-blind phase III trial reported in The New England Journal of Medicine, Gilbert et al assessed adding bevacizumab (Avastin), which is currently approved in recurrent glioblastoma, to radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. The addition of bevacizumab...

cns cancers

No Benefit of Dose-Dense vs Standard Temozolomide in Newly Diagnosed Glioblastoma, MGMT Methylation Associated With Better Survival

Dose-dense temozolomide results in depletion of O6-methylguanine-DNA methyltransferase (MGMT)—a potential determinant of treatment response—in blood mononuclear cells and possibly in tumors. In a phase III trial (Radiation Therapy Oncology Group [RTOG] 0525) reported in the Journal ...

cns cancers

ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival

A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...

Advertisement

Advertisement



;
Advertisement